高脂血癥是因多種原因導致脂質代謝紊亂的一種病理狀態(tài)，可引起動脈粥樣硬化等多種疾病的發(fā)生，嚴重影響患者的生活質量。目前化學藥治療存在不良反應大、耐藥等缺點。而中藥用于治療高脂血癥的歷史悠久，臨床經驗豐富，且以不良反應少、用藥依從性好的優(yōu)點成為近幾年研究的熱點。通過查閱分析國內外有關中藥干預高脂血癥信號通路的文獻，歸納總結出6條中藥干預高脂血癥相關信號通路，分別為過氧化物酶體增殖物激活受體（PPAR）信號通路、腺苷酸激活蛋白激酶（AMPK）信號通路、環(huán)磷酸腺苷（cAMP）信號通路、脂肪細胞因子（Adipocytokine）信號通路、法尼酯衍生物X受體（FXR）-小異二聚體伴侶（SHP）信號通路及磷脂酰肌醇-3-激酶（PI3K）-絲氨酸/蛋白激酶B（Akt）信號通路，以期為治療高脂血癥的藥物研發(fā)提供參考。

Hyperlipidemia is a pathological condition of lipid metabolism disorder due to a variety of reasons, which can cause atherosclerosis and other diseases, and seriously affect patients' quality of life. At present, western medicine in the treatment of hyperlipidemia has many disadvantages such as high side effects, drug resistance and so on. However, traditional Chinese medicine has a long history in the treatment of hyperlipidemia, with rich clinical experience. Traditional Chinese medicine has become a hot topic in recent years due to its advantages of less side effects and good compliance. In this paper, by consulting and analyzing the local and international literatures on the signaling pathway of traditional Chinese medicine in the treatment of hyperlipidemia, the six signaling pathways of traditional Chinese medicine intervention on signaling pathway associated with hyperlipidemia are summarized, which were PPAR, AMPK, cAMP, Adipocytokine, FXR-SHP and PI3K-AKT, respectively, so as to provide reference for the research and development of drugs for hyperlipidemia.

R926

國家自然科學基金資助項目（81973557）；天津市自然科學基金重點項目（20JCZDJC00010）；國家科技重大專項（2018ZX09737-019、2018ZX09303-024）；釋藥技術與藥代動力學國家重點實驗室（天津藥物研究院）開發(fā)課題資助（010162001）